NTI164 clinical trials
Also written NTI164 and FEN164.
How each study uses NTI164 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the NTI164 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2023 (2); 1 more planned to start later
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Fenix Innovation Group (6)
Studies
Open first, then newest update. How each study uses NTI164 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- NTI164 in Autism Spectrum DisorderNot yet recruitingPhase 3Fenix Innovation GroupNCT07257939Written as NTI164
- Efficacy and Safety of NTI164 in Children and Young Adults With Rett SyndromeNot yet recruitingPhase 2/3Fenix Innovation GroupNCT07257978Written as NTI164
- Evaluating the Efficacy of NTI164 in Young People With Autism Spectrum DisorderCompletedPhase 2/3Fenix Innovation GroupNCT05626959Written as NTI164
- Assessing the Safety and Efficacy of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) in the Treatment of Rett Syndrome (RTT)CompletedPhase 1/2Fenix Innovation GroupNCT06621043Written as NTI164
- Investigating The Effects Of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) On Paediatric Acute-onset Neuropsychiatric Syndrome (PANS)CompletedPhase 1/2Fenix Innovation GroupNCT06621888Written as NTI164
- NTI164 Human PK StudyCompletedPhase 1Fenix Innovation GroupNCT06713447Written as NTI164